3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
40
Neoplasms
5
Colorectal Neoplasms
5
Neoplasm Metastasis
3
Resectable Pancreatic Cancer
2
Rectal Neoplasms
2
Carcinoma, Hepatocellular
2
Adenocarcinoma
2
Urachal cancer
1
Stomach Neoplasms
1
Pancreatic Ductal Adenocarcinoma (PDAC)
1
Pancreatic Cancer Metastatic
1
Pancreatic Adenocarcinoma
1
Neoplasms, Basal Cell
1
Locally Advanced Pancreatic Adenocarcinoma
1
Localized Pancreatic Adenocarcinoma
1
Gastrointestinal Neoplasms
1
Gastroesophageal Adenocarcinoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Cancer Metastatic
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Islet Cell
1
Borderline Resectable Pancreatic Cancer
1
Biliary Tract Neoplasms
1
Ampullary Adenocarcinoma
1
Interventions
Gemcitabine
2
toripalimab
1
surufatinib
1
sintilimab
1
folfirinox
1
chloroquine diphosphate
1
balstilimab
1
Taxes
1
Oxaliplatin
1
Irinotecan
1
Immune Checkpoint Inhibitors
1
Drug Therapy
1
Cisplatin
1
Chloroquine
1
Celecoxib
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Pancreatic Cancer Metastatic
×
folfirinox
×
Clear all
NCT04469556
2026-02-20
PASS-01
University Health Network, Toronto
Phase 2
Completed
150 enrolled